All In Biotech

Drug Trial Radar · NCT05607537

A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants

An Open-Label, Single-Center, 2-Part, Parallel Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of [14C]E7386 in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Oct 17, 2022

Primary completion

Aug 31, 2023

Study completion Aug 31, 2023

Sponsor

Lead sponsor
Eisai LimitedEisai
Sponsor type
Industry
First posted
Nov 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Male only, from 30 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the absolute bioavailability of E7386 following a single oral dose of E7386 as a one 40 milligram (mg) immediate release (IR) tablet and concomitant intravenous (IV) microdose of (14C)E7386 (100 mcg \[microgram\]) solution for Part 1 and to determine the pharmacokinetic (PK) and excretion of E7386 following a single 40 mg powder in capsule (PIC) oral administration of (14C)E7386 for Part 2.

Conditions

  • Healthy Volunteers

Interventions

  • E7386 TabletDrug

    E7386 40 mg tablet.

  • (14C)E7386 CapsuleDrug

    (14C)E7386 40 mg capsule.

  • (14C)E7386Drug

    (14C)E7386 administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1, %F: Percent Absolute Oral Bioavailability for (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  2. Part 1, Cmax: Maximum Observed Plasma Concentration for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  3. Part 1, Tlag: Time Delay Between Drug Administration and the Onset of Absorption for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  4. Part 1, Tmax: Time to Reach Maximum Observed Plasma Concentration (Cmax) for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  5. Part 1, AUC(0-12h): Area Under the Plasma Concentration-time Curve From Time Zero to 12 hours Post-dose for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 12 hours post-dose
  6. Part 1, AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time Zero to 24 hours Post-dose for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 24 hours post-dose
  7. Part 1, AUC(0-last): Area Under the Plasma Concentration-time Curve from Time 0 to Time of the Last Measurable Concentration for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  8. Part 1, AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  9. Part 1, t1/2: Apparent Terminal Elimination Phase Half-life for Total Radioactivity, (14C)E7386 and E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  10. Part 1, MRT: Mean Residence Time of (14C)E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  11. Part 1, CL: Total Clearance of (14C)E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  12. Part 1, CL/F: Apparent Total Body Clearance of E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  13. Part 1, Vss: Volume of Distribution at Steady State of (14C)E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  14. Part 1, Vz/F: Apparent Volume of Distribution at Terminal Phase of E7386Time frame: Pre-dose (0 hour) up to 96 hours post-dose
  15. Part 1, Fa: Percentage of Absorbed Dose Using Total Radioactivity in UrineTime frame: Pre-dose (0 hour) up to 96 hours post-dose
  16. Part 2, Cmax: Maximum Observed Concentration for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
  17. Part 2, Tlag: Time Delay Between Drug Administration and the Onset of Absorption for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
  18. Part 2, Tmax: Time to Reach Maximum Observed Concentration (Cmax) for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
  19. Part 2, AUC(0-12h): Area Under the Concentration-time Curve From Time Zero to 12 hours Post-dose for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 12 hours post-dose
  20. Part 2, AUC(0-24h): Area Under the Concentration-time Curve From Time Zero to 24 hours Post-dose for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 24 hours post-dose
  21. Part 2, AUC(0-last): Area Under the Concentration-time Curve from Time 0 to Time of the Last Measurable Concentration for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
  22. Part 2, AUC(0-inf): Area Under the Concentration-time Curve From Time Zero to Infinite Time for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
  23. Part 2, t1/2: Apparent Terminal Elimination Phase Half-life for Total Radioactivity and E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
  24. Part 2, CL/F: Apparent Total Body Clearance of E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
  25. Part 2, Vz/F: Apparent Volume of Distribution at Terminal Phase of E7386Time frame: Pre-dose (0 hour) up to 480 hours post-dose
  26. Part 2, feu: Percentage of Administered Radioactive Dose Excreted in Urine for Total RadioactivityTime frame: Day -1 (Baseline) up to Day 49
  27. Part 2, Cumulative feu(0-tlast): Cumulative Radioactive Dose Excreted in Urine From Time 0 to Time of the Last Measurable ConcentrationTime frame: Day -1 (Baseline) up to Day 49
  28. Part 2, fef: Percentage of Total Radioactivity Recovered in Feces Relative to the Administered Radioactive DoseTime frame: Day -1 (Baseline) up to Day 49
  29. Part 2, Cumulative fef(0-tlast): Cumulative Radioactive Dose Excreted in Feces From Time 0 to Time of the Last Measurable ConcentrationTime frame: Day -1 (Baseline) up to Day 49
  30. Part 2, feu+ef: Percentage of Total Radioactivity Recovered in Combined Urine and Feces Relative to the Administered Radioactive DoseTime frame: Day -1 (Baseline) up to Day 49
  31. Part 2, Cumulative feu+ef(0-tlast): Cumulative Radioactive Dose excreted in Combined Excreta (Urine and Feces) From Time Zero to Time of the Last Measurable ConcentrationTime frame: Day -1 (Baseline) up to Day 49
  32. Part 2, Fa: Percentage of Absorbed Dose Using Total Radioactivity in UrineTime frame: Day -1 (Baseline) up to Day 49

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Labcorp Clinical Research Unit

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.